Wells Fargo & Company MN Boosts Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

2025-04-26T07:50:48Z

Wells Fargo & Company MN grew its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 35.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,255 shares of the medical device company’s stock after buying an additional 16,163 shares during the quarter. Wells Fargo & Company MN’s holdings in Tandem Diabetes Care were worth $2,206,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Integrated Quantitative Investments LLC bought a new stake in Tandem Diabetes Care during the fourth quarter worth $1,149,000. Landscape Capital Management L.L.C. increased its position in shares of Tandem Diabetes Care by 44.9% during the 4th quarter. Landscape Capital Management L.L.C. now owns 19,635 shares of the medical device company’s stock valued at $707,000 after purchasing an additional 6,081 shares during the last quarter. ExodusPoint Capital Management LP raised its stake in shares of Tandem Diabetes Care by 331.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 254,057 shares of the medical device company’s stock worth $9,151,000 after purchasing an additional 195,194 shares during the period. Trexquant Investment LP boosted its holdings in shares of Tandem Diabetes Care by 53.8% in the 4th quarter. Trexquant Investment LP now owns 211,206 shares of the medical device company’s stock worth $7,608,000 after buying an additional 73,838 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Tandem Diabetes Care by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,533,828 shares of the medical device company’s stock worth $55,261,000 after buying an additional 8,012 shares during the last quarter.

Get Tandem Diabetes Care alerts:

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM opened at $18.06 on Friday. The stock has a fifty day moving average of $20.17 and a 200-day moving average of $29.29. The stock has a market cap of $1.20 billion, a PE ratio of -9.36 and a beta of 1.52. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Citigroup downgraded shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Barclays decreased their price target on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Canaccord Genuity Group reiterated a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average target price of $43.81.

Check Out Our Latest Stock Analysis on TNDM

Insider Buying and Selling at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Company Profile

(Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.